R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Unknown 60 enrolled The First Affiliated Hospital with Nanjing Medical University

NaSingle-groupOpen-labelTreatment

Summary

Based on the modified R-MINE of mitoxantrone hydrochloride liposome, the corresponding targeted drug (X) was added according to the genotyping detected by second-generation gene sequencing (NGS) to explore the effectiveness and safety of R-MINE+X in the treatment of recurrent/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Timeline

Start: 2023-04-15
Primary completion: 2024-01-01
Completion: 2025-01-01

Publications

Liang JH, Zhang XY, Bi LT, Qin WW, Su LP, Liu JB, Wu JZ, Yin H, Kong YL, Shen HR, Li JY, Li Y, Wang L, Xu W. R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study. BMC Med. 2026 Jul 9. doi: 10.1186/s12916-026-05051-z. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etoposide	Small molecule	65 mg/m2	—
Subject	Ifosfamide	Small molecule	1.33 g	—
Subject	Lenalidomide	Other / unclassified	25 mg	—
Subject	Mitoxantrone hydrochloride liposome	Unknown	20 mg/m2	—
Subject	Orelabrutinib	Small molecule	150 mg	—
Subject	Penpulimab	Monoclonal antibody	200 mg	—
Subject	Rituximab	Monoclonal antibody	375 mg/m2	—
Subject	Tucidinostat	Small molecule	20 mg	—

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications